INmune Bio (NASDAQ:INMB - Get Free Report) is expected to be announcing its Q2 2025 earnings results after the market closes on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.37) per share for the quarter.
INmune Bio (NASDAQ:INMB - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.43) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.43). The firm had revenue of $0.05 million for the quarter. On average, analysts expect INmune Bio to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
INmune Bio Trading Down 6.2%
Shares of INMB stock traded down $0.17 during trading hours on Friday, hitting $2.56. The stock had a trading volume of 966,162 shares, compared to its average volume of 2,237,181. INmune Bio has a one year low of $1.89 and a one year high of $11.64. The stock's 50-day moving average price is $4.95 and its two-hundred day moving average price is $6.91.
Wall Street Analyst Weigh In
INMB has been the topic of several recent research reports. Maxim Group decreased their price objective on INmune Bio from $30.00 to $8.00 and set a "buy" rating on the stock in a report on Wednesday, July 2nd. Scotiabank restated a "sector underperform" rating on shares of INmune Bio in a research report on Tuesday, July 1st. Raymond James Financial lowered shares of INmune Bio from a "moderate buy" rating to a "hold" rating in a research report on Monday, June 30th. Finally, BTIG Research reissued a "neutral" rating on shares of INmune Bio in a research note on Tuesday, July 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $18.40.
Check Out Our Latest Analysis on INMB
Institutional Trading of INmune Bio
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Rhumbline Advisers increased its position in INmune Bio by 14.4% during the first quarter. Rhumbline Advisers now owns 19,153 shares of the company's stock valued at $150,000 after acquiring an additional 2,409 shares during the last quarter. Royal Bank of Canada lifted its holdings in shares of INmune Bio by 44.8% in the 1st quarter. Royal Bank of Canada now owns 29,863 shares of the company's stock worth $233,000 after acquiring an additional 9,236 shares during the last quarter. Finally, Jane Street Group LLC bought a new position in INmune Bio during the 1st quarter valued at about $142,000. Hedge funds and other institutional investors own 12.72% of the company's stock.
About INmune Bio
(
Get Free Report)
INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
See Also
Before you consider INmune Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and INmune Bio wasn't on the list.
While INmune Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
